Business
Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs
ADX-629 Expected to Begin Phase 2 Clinical Trials in COVID-19 Respiratory Compromise, Atopic Asthma, and Psoriasis in 2020 Type C Meeting Scheduled with FDA
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":"\n\nADX-629 Expected to Begin Phase 2 Clinical Trials in COVID-19 Respiratory Compromise, Atopic Asthma, and Psoriasis in 2020\n\n\nType C Meeting Scheduled with FDA to Discuss Remaining NDA Requirements for Reproxalap in Dry Eye Disease \n\n\nResults from Phase 3 INVIGORATE Trial of Reproxalap in Allergic Conjunctivitis Expected in First Half of 2021 \n\n\nCash Runway Extended into 2022 \n\n\nManagement to Host Conference Call at 8:00 a.m. ET Today \n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2020, announced new clinical trials in systemic inflammatory diseases, and provided an update on ocular disease programs.\n\n\n“Based on the success of the novel RASP inhibitor ADX-629 in Phase 1 clinical testing, we are pleased to announce a new comprehensive clinical initiative in systemic inflammatory diseases, complementing our late-stage pipeline in ocular disease,” said Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Although the COVID-19 pandemic has affected clinical trial enrollment timelines, our cash position remains strong, and we are extending our projected cash runway guidance into 2022.”\n\n\nNew Clinical Programs in Systemic Inflammatory Diseases\n\n\nAldeyra plans to assess the activity of ADX-629 in three types of severe inflammation: cytokine release syndrome, autoimmune disease, and allergy. In preclinical models, ADX-629 treatment reduced levels of TH1, TH2, and TH17-related cytokines, suggesting potential activity across a broad array of inflammatory diseases. The timing of clinical trial initiation depends, in part, on restrictions related to COVID-19, the availability of clinical research facilities and staffing, and the ability to recruit patients.\n\n\n\nCOVID-19 Respiratory Compromise: A Phase 2 clinical trial of ADX-629 is expected in subjects with COVID-19-associated respiratory compromise, defined as hypoxia and pulmonary radiographic involvement, immediately following admission to the hospital. Severe inflammation, characterized in part by cytokine release syndrome, leads to acute respiratory distress syndrome an...